GENFLEET-B(02595) proposes to repurchase H shares up to a maximum of HK$350 million.

date
12:12 29/06/2026
avatar
GMT Eight
JinFang Pharmaceuticals-B (02595) announced that on June 29, 2026, the board of directors formally decided to exercise the authorization to repurchase shares, intending to repurchase H shares (share repurchase) in the open market from time to time, with a maximum amount not exceeding 350 million Hong Kong dollars. The share repurchase period will expire upon the expiration of the authorization to repurchase shares. The company will repurchase shares in compliance with the Securities Listing Rules of the Hong Kong Stock Exchange.
GENFLEET-B (02595) Announcement, on June 29, 2026, the Board of Directors officially decided to exercise the authorization to repurchase shares, intending to repurchase H shares (share repurchase) on the open market from time to time, with a maximum amount not exceeding HK$350 million, and the share repurchase period expires upon the expiration of the share repurchase authorization. The company will repurchase shares in compliance with the listing rules of the Hong Kong Stock Exchange. The Board believes that the current trading price of the shares undervalues the company's intrinsic value and development prospects, and that the share repurchase will enhance shareholder value. The share repurchase demonstrates the Board's confidence in the company's long-term development and will only be carried out when the Board continuously evaluates the company's business prospects, financial condition, stock price performance, and market environment, and deems it appropriate and in the overall interests of the company and shareholders.